Bone Metastasis - Market Insight, Epidemiology and Market Forecast - 2028

January 2019 | 100 pages | ID: B5E02D1EC47EN
DelveInsight

Abstracts

This report can be delivered to the clients within 7-10 Business Days

DelveInsight's 'Bone Metastasis - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Bone Metastasis epidemiology and market outlook for the 7MM.

MARKETS COVERED

• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Bone Metastasis Understanding and Treatment Algorithm

The market report provides the overview of the Bone Metastasis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.
Bone Metastasis Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Bone Metastasis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.
Bone Metastasis Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.
Bone Metastasis Market Outlook

The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Bone Metastasis market.
Bone Metastasis Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.
Bone Metastasis Report Insights

• Patient Population in Bone Metastasis
• Therapeutic Approaches in Bone Metastasis
• Bone Metastasis Pipeline Analysis
• Bone Metastasis Market Size and Trends
• Bone Metastasis Market Opportunities
• Impact of upcoming Therapies in Bone Metastasis

Bone Metastasis Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Bone Metastasis Report Assessment

• Current Treatment Practices in Bone Metastasis
• Unmet Needs in Bone Metastasis
• Market Attractiveness
• Market Drivers and Barriers

KEY BENEFITS

• The report will help to develop Business Strategies by understanding the trends shaping and driving the Bone Metastasis market
• Organize sales and marketing efforts by identifying the best opportunities for Bone Metastasis market
• To understand the future market competition in the Bone Metastasis market.

Contents

1. REPORT INTRODUCTION

2. BONE METASTASIS MARKET OVERVIEW AT A GLANCE

2.1. Market Share Distribution of Bone Metastasis in 2016
2.2. Market Share Distribution of Bone Metastasis in 2028

3. DISEASE BACKGROUND AND OVERVIEW: BONE METASTASIS

3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Bone Metastasis in 7MM
4.3. Total Prevalent Patient Population of Bone Metastasis in 7MM – By Countries

5. EPIDEMIOLOGY OF BONE METASTASIS BY COUNTRIES

5.1. United States
  5.1.1. Assumptions and Rationale
  5.1.2. Prevalent/Incident Cases of the Bone Metastasis
  5.1.3. Sub-Type Specific cases of the Bone Metastasis
  5.1.4. Sex- Specific Cases of the Bone Metastasis
  5.1.5. Diagnosed Cases of the Bone Metastasis
  5.1.6. Treatable Cases of the Bone Metastasis
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
  5.4.1. Assumptions and Rationale
  5.4.2. Prevalent/Incident Cases of the Bone Metastasis
  5.4.3. Sub-Type Specific cases of the Bone Metastasis
  5.4.4. Sex- Specific Cases of the Bone Metastasis
  5.4.5. Diagnosed Cases of the Bone Metastasis
  5.4.6. Treatable Cases of the Bone Metastasis
5.5. France
  5.5.1. Assumptions and Rationale
  5.5.2. Prevalent/Incident Cases of the Bone Metastasis
  5.5.3. Sub-Type Specific cases of the Bone Metastasis
  5.5.4. Sex- Specific Cases of the Bone Metastasis
  5.5.5. Diagnosed Cases of the Bone Metastasis
  5.5.6. Treatable Cases of the Bone Metastasis
5.6. Italy
  5.6.1. Assumptions and Rationale
  5.6.2. Prevalent/Incident Cases of the Bone Metastasis
  5.6.3. Sub-Type Specific cases of the Bone Metastasis
  5.6.4. Sex- Specific Cases of the Bone Metastasis
  5.6.5. Diagnosed Cases of the Bone Metastasis
  5.6.6. Treatable Cases of the Bone Metastasis
5.7. Spain
  5.7.1. Assumptions and Rationale
  5.7.2. Prevalent/Incident Cases of the Bone Metastasis
  5.7.3. Sub-Type Specific cases of the Bone Metastasis
  5.7.4. Sex- Specific Cases of the Bone Metastasis
  5.7.5. Diagnosed Cases of the Bone Metastasis
  5.7.6. Treatable Cases of the Bone Metastasis
5.8. United Kingdom
  5.8.1. Assumptions and Rationale
  5.8.2. Prevalent/Incident Cases of the Bone Metastasis
  5.8.3. Sub-Type Specific cases of the Bone Metastasis
  5.8.4. Sex- Specific Cases of the Bone Metastasis
  5.8.5. Diagnosed Cases of the Bone Metastasis
  5.8.6. Treatable Cases of the Bone Metastasis
5.9. Japan
  5.9.1. Assumptions and Rationale
  5.9.2. Prevalent/Incident Cases of the Bone Metastasis
  5.9.3. Sub-Type Specific cases of the Bone Metastasis
  5.9.4. Sex- Specific Cases of the Bone Metastasis
  5.9.5. Diagnosed Cases of the Bone Metastasis
  5.9.6. Treatable Cases of the Bone Metastasis

6. CURRENT TREATMENT & MEDICAL PRACTICES

6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. UNMET NEEDS OF THE BONE METASTASIS

8. MARKETED THERAPIES

8.1. Drug A: Company
  8.1.1. Drug Description
  8.1.2. Mechanism of Action
  8.1.3. Regulatory Milestones
  8.1.4. Advantages & Disadvantages
  8.1.5. Product Profile
8.2. Drug B: Company
  8.2.1. Drug Description
  8.2.2. Mechanism of Action
  8.2.3. Regulatory Milestones
  8.2.4. Advantages & Disadvantages
  8.2.5. Product Profile

9. PIPELINE THERAPIES – AT A GLANCE

10. KEY CROSS COMPETITION

11. EMERGING THERAPIES FOR BONE METASTASIS

11.1. Drug C: Company
  11.1.1. Drug Description
  11.1.2. Clinical Trials Details
  11.1.3. Safety and Efficacy Profile
  11.1.4. Advantages & Disadvantages
  11.1.5. Pipeline Development Activities
  11.1.6. Product Profile
11.2. Drug D: Company
  11.2.1. Drug Description
  11.2.2. Clinical Trials Details
  11.2.3. Safety and Efficacy Profile
  11.2.4. Advantages & Disadvantages
  11.2.5. Pipeline Development Activities
  11.2.6. Product Profile

12. BONE METASTASIS: 7MM MARKET ANALYSIS

12.1. 7MM Market Size of Bone Metastasis
12.2. 7MM Percentage Share of drugs marketed for Bone Metastasis
12.3. 7MM Market Sales of Bone Metastasis by Products

13. BONE METASTASIS: COUNTRY-WISE MARKET ANALYSIS

13.1. United States
  13.1.1. Market Size of Bone Metastasis in United States
  13.1.2. Percentage Share of drugs marketed for Bone Metastasis in United States
  13.1.3. Market Sales of Bone Metastasis by Products in United States
  13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
  13.2.1. Germany
    13.2.1.1. Market Size of Bone Metastasis in Germany
    13.2.1.2. Percentage Share of drugs marketed for Bone Metastasis in Germany
    13.2.1.3. Market Sales of Bone Metastasis by Products in Germany
    13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.2. France
    13.2.2.1. Market Size of Bone Metastasis in France
    13.2.2.2. Percentage Share of drugs marketed for Bone Metastasis in France
    13.2.2.3. Market Sales of Bone Metastasis by Products in France
    13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.3. Italy
    13.2.3.1. Market Size of Bone Metastasis in Italy
    13.2.3.2. Percentage Share of drugs marketed for Bone Metastasis in Italy
    13.2.3.3. Market Sales of Bone Metastasis by Products in Italy
    13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.4. Spain
    13.2.4.1. Market Size of Bone Metastasis in Spain
    13.2.4.2. Percentage Share of drugs marketed for Bone Metastasis in Spain
    13.2.4.3. Market Sales of Bone Metastasis by Products in Spain
    13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.5. United Kingdom
    13.2.5.1. Market Size of Bone Metastasis in United Kingdom
    13.2.5.2. Percentage Share of drugs marketed for Bone Metastasis in United Kingdom
    13.2.5.3. Market Sales of Bone Metastasis by Products in United Kingdom
    13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
  13.3.1. Market Size of Bone Metastasis in Japan
  13.3.2. Percentage Share of drugs marketed for Bone Metastasis in Japan
  13.3.3. Market Sales of Bone Metastasis by Products in Japan
  13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. MARKET DRIVERS

15. MARKET BARRIERS

16. APPENDIX

17. REPORT METHODOLOGY

17.1. Sources

18. DELVEINSIGHT CAPABILITIES

19. DISCLAIMER

20. ABOUT DELVEINSIGHT

Indication Specific

List Of Tables

LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Bone Metastasis in 7MM
Table 2: Total Prevalent/Incident Cases of the Bone Metastasis in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Bone Metastasis in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Bone Metastasis in United States (2016-2028)
Table 5: Sex- Specific Cases of the Bone Metastasis in United States (2016-2028)
Table 6: Diagnosed Cases of the Bone Metastasis in United States (2016-2028)
Table 7: Treatable Cases of the Bone Metastasis in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Bone Metastasis in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Bone Metastasis in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Bone Metastasis in Germany (2016-2028)
Table 11: Diagnosed Cases of the Bone Metastasis in Germany (2016-2028)
Table 12: Treatable Cases of the Bone Metastasis in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Bone Metastasis in France (2016-2028)
Table 14: Sub-Type Specific cases of the Bone Metastasis in France (2016-2028)
Table 15: Sex- Specific Cases of the Bone Metastasis in France (2016-2028)
Table 16: Diagnosed Cases of the Bone Metastasis in France (2016-2028)
Table 17: Treatable Cases of the Bone Metastasis in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Bone Metastasis in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Bone Metastasis in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Bone Metastasis in Italy (2016-2028)
Table 21: Diagnosed Cases of the Bone Metastasis in Italy (2016-2028)
Table 22: Treatable Cases of the Bone Metastasis in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Bone Metastasis in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Bone Metastasis in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Bone Metastasis in Spain (2016-2028)
Table 26: Diagnosed Cases of the Bone Metastasis in Spain (2016-2028)
Table 27: Treatable Cases of the Bone Metastasis in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Bone Metastasis in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Bone Metastasis in UK (2016-2028)
Table 30: Sex- Specific Cases of the Bone Metastasis in UK (2016-2028)
Table 31: Diagnosed Cases of the Bone Metastasis in UK (2016-2028)
Table 32: Treatable Cases of the Bone Metastasis in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Bone Metastasis in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Bone Metastasis in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Bone Metastasis in Japan (2016-2028)
Table 36: Diagnosed Cases of the Bone Metastasis in Japan (2016-2028)
Table 37: Treatable Cases of the Bone Metastasis in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Bone Metastasis in USD MM (2016-2028)
Table 42:7MM- Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Bone Metastasis in USD MM (2016-2028)
Table 45: United States-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Bone Metastasis in USD MM (2016-2028)
Table 48: Germany-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Bone Metastasis in USD MM (2016-2028)
Table 51: France-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Bone Metastasis in USD MM (2016-2028)
Table 54: Italy-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Bone Metastasis in USD MM (2016-2028)
Table 57: Spain-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Bone Metastasis in USD MM (2016-2028)
Table 60:UK-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Bone Metastasis in USD MM (2016-2028)
Table 63: Japan-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)

List Of Figures

LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Bone Metastasis in 7MM
Figure 2: Total Prevalent/Incident Cases of the Bone Metastasis in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Bone Metastasis in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Bone Metastasis in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Bone Metastasis in United States (2016-2028)
Figure 6: Diagnosed Cases of the Bone Metastasis in United States (2016-2028)
Figure 7: Treatable Cases of the Bone Metastasis in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Bone Metastasis in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Bone Metastasis in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Bone Metastasis in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Bone Metastasis in Germany (2016-2028)
Figure 12: Treatable Cases of the Bone Metastasis in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Bone Metastasis in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Bone Metastasis in France (2016-2028)
Figure 15: Sex- Specific Cases of the Bone Metastasis in France (2016-2028)
Figure 16: Diagnosed Cases of the Bone Metastasis in France (2016-2028)
Figure 17: Treatable Cases of the Bone Metastasis in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Bone Metastasis in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Bone Metastasis in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Bone Metastasis in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Bone Metastasis in Italy (2016-2028)
Figure 22: Treatable Cases of the Bone Metastasis in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Bone Metastasis in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Bone Metastasis in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Bone Metastasis in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Bone Metastasis in Spain (2016-2028)
Figure 27: Treatable Cases of the Bone Metastasis in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Bone Metastasis in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Bone Metastasis in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Bone Metastasis in UK (2016-2028)
Figure 31: Diagnosed Cases of the Bone Metastasis in UK (2016-2028)
Figure 32: Treatable Cases of the Bone Metastasis in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Bone Metastasis in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Bone Metastasis in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Bone Metastasis in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Bone Metastasis in Japan (2016-2028)
Figure 37: Treatable Cases of the Bone Metastasis in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Bone Metastasis in USD MM (2016-2028)
Figure 42:7MM- Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Bone Metastasis in USD MM (2016-2028)
Figure 45: United States-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Bone Metastasis in USD MM (2016-2028)
Figure 48: Germany-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Bone Metastasis in USD MM (2016-2028)
Figure 51: France-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Bone Metastasis in USD MM (2016-2028)
Figure 54: Italy-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Bone Metastasis in USD MM (2016-2028)
Figure 57: Spain-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Bone Metastasis in USD MM (2016-2028)
Figure 60:UK-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Bone Metastasis in USD MM (2016-2028)
Figure 63: Japan-Market Share Bone Metastasis by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Bone Metastasis by Therapies in USD MM (2016-2028)